Amgen Just Gave Its Shareholders Great News
Key PointsAmgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi.
Amgen, a healthcare company, has delivered excellent news to its shareholders this year. The stock has surged more than 40%, making it a safer and larger investment option compared to the recent buzz around Moderna's cancer vaccine. Amgen's promising cancer treatment, Imdelltra, has shown significant promise in reducing the risk of death in patients with extensive-stage small cell lung cancer when used in conjunction with AstraZeneca's Imfinzi.
This groundbreaking combination treatment has demonstrated a 58% decrease in mortality rates, with a median survival time of 21.1 months compared to 12.7 months when using Imfinzi alone. Dr. Paul Burton, Amgen's chief medical officer, is optimistic about the potential transformation of the standard of care for patients. Imdelltra has already been one of Amgen's top-performing drugs, generating 115% growth through the first six months of 2026, amounting to $288 million.
With 22 products growing by double digits in the second quarter and 17 products generating over $1 billion in annual revenue, Amgen's growth potential appears significant. The stock, currently trading at a reasonable forward price-to-earnings multiple of 19, may have room to rise further, especially considering its vast pipeline of development projects.
Growth-oriented investors may find ample incentive to hold onto Amgen's stock, as its valuation could climb significantly in the coming months and years.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
